Skip to main content

Year: 2023

Pisco Market to Worth USD 1,057.8 Million by 2027 | 130 Pages Research Report

Key Companies in Pisco Market are Pisco Portón (Ica, Peru), Catan Pisco (Chicago, United States), Pisco MalPaso (Coquimbo, Chile), Barton Solvent Inc. (Peru), Cooperativa Agricola Pisquera Elqui Ltda (Santiago, Chile), Compañia Cervecerias Unidas (Las Condes, Chile), Pisquera Tulahuen SpA (Monte Patria, Chile), La Diablada Pisco (Peru), Bauzá (Chile), Macchu Pisco (Peru)Pisco MarketPisco Market SizePune, India, Dec. 06, 2023 (GLOBE NEWSWIRE) — The global pisco market size is projected to reach USD 1,057.8 million by 2027, exhibiting a CAGR of 6.2% during the forecast period. Increasing awareness about the potential health benefits of pisco will play a central role in augmenting the development of this market. Pisco is a certain type of brandy that is derived from fermented grape juice. The drink is native to Chile and...

Continue reading

Form 8.5 (EPT/NON-RI) – Velocys Plc

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Shore Capital Stockbrokers Ltd(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Velocys Plc(c)        Name of the party to the offer with which exempt principal trader is connected: Velocys Plc(d)        Date dealing undertaken: 05 December 2023(e)        Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer? No2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER (a)        Purchases and salesClass of...

Continue reading

Form 8.3 – [abrdn EUROPEAN LOGISTICS INCOME PLC – 05 12 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree abrdn EUROPEAN LOGISTICS INCOME PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

[Press Release] iliad SA launches a tender offer on its existing bonds maturing in February 2024 and October 2024 and intends to issue new Euro denominated senior unsecured bonds

PRESS RELEASE Paris, December 6, 2023   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. iliad SA launches a tender offer on its existing bonds maturing in February 2024 and October 2024 and intends to issue new Euro denominated senior unsecured bonds   iliad SA (the “Company”) announces today the launch of a tender offer on its outstanding €600,000,000 0.750 per cent. Bonds due 11 February 2024 (ISIN: FR0014001YE4) and its €650,000,000 1.500 per cent. Bonds due 14 October 2024 (ISIN: FR0013287273), admitted to trading on the Luxembourg Stock Exchange (the “Existing Bonds”) (the “Tender Offer”) and its intention to issue new Euro denominated senior unsecured bonds (the “New Bonds”), subject to market...

Continue reading

Clariant shuts its sunliquid® bioethanol plant in Romania

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LRStrategic review concluded: Board of Directors has decided to close bioethanol plant in Podari, Romania, and to downsize related activities in Germany Asset impairments of approximately CHF 110 million and provisions relating to closure of approximately CHF 60 – 90 million in Q4 2023 Anticipated cash impact of CHF 110 – 140 million in 2024 Continued focus on execution of Clariant’s purpose-led growth strategyMUTTENZ, DECEMBER 6, 2023 Clariant, a sustainability-focused specialty chemical company, today announced its decision to shut down its sunliquid® bioethanol production in Podari, Romania, and to downsize related activities of the business line Biofuels & Derivatives in Germany (Straubing, Planegg and Munich). After developing the sunliquid® technology, Clariant had taken the decision...

Continue reading

LHV Group and LHV Pank intend to nominate Liisi Znatokov as a candidate for member of the Supervisory Board

On the proposal of the Nomination Committee, the Supervisory Board of AS LHV Group has decided to nominate Liisi Znatokov (formerly Himma) as a candidate for a new member of the Supervisory Board. The proposal for the election of a new member of the Supervisory Board will be submitted to the shareholders at the Annual General Meeting to be held on 20 March 2024. Election to the Supervisory Board will be subject to the approval of the European Central Bank for compliance with the eligibility requirements. Her term of office is planned to be three years. On the proposal of the Nomination Committee, the Supervisory Board of AS LHV Pank also plans to submit the sole shareholder the proposal for the election of Liisi Znatokov as an additional member of the Supervisory Board of LHV Pank with the prior approval of the European Central Bank. She...

Continue reading

BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease

PRESS RELEASE – INSIDE INFORMATION         Biosenic signs term sheet with SPRIM Global Investments (TrialCap fund) for up to USD 8 million debt financing and USD 800,000 equity investment as a first decisive, financing step towards a Phase 3 clinical trial for its ground-breaking auto-immune medication, a first-in-class drug oral arsenic salt. Mont-Saint-Guibert, Belgium, December 6, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announces that it has signed a term sheet with Singapore based fund TrialCap Pte. Ltd. (the “Term Sheet”) and/or other lenders (the “Lender”) for a proposed debt and equity financing. BioSenic is seeking the funds to continue...

Continue reading

Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressVIVIAD and VIVA-MIND studies both advancing as planned at 600mg twice daily following positive DSMB decisions; VIVIAD safety update with cut-off as of November 20, 2023, confirms low level of discontinuations On track to report VIVIAD final topline Phase 2b data during end of Q1/2024 Commenced preparations for VIVALONG, an open-label extension study Unveiling focused growth strategy leveraging varoglutamstat and VIVIAD and investing in QPCT/L small molecule platform Chief Financial Officer transition with promotion of Anne Doering, CFA, effective March 1, 2024 Management to host conference call today at 3:00 pm CET (9:00 am EST)Halle (Saale) / Munich, Germany, December 6, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam:...

Continue reading

2024 Financial Calendar of EfTEN United Property Fund

EfTEN Capital AS wishes to inform all investors of the EfTEN United Property Fund’s financial calendar for the 2024 financial year. We plan to disclose financial results according to the following schedule: 08.02.2024   Unaudited results for Q4 2023 and 12 months 202307.03.2024   Audited results for 202330.04.2024   Q1 interim results08.08.2024  Q2 interim results        31.10.2024    Q3 interim resultsKristjan TamlaManaging DirectorPhone 655 9515E-mail: kristjan.tamla@eften.ee  

Continue reading

Approval of delisting of ONE swiss bank SA’s registered shares from SIX Swiss Exchange

   6 December 2023 Ad hoc announcement pursuant to Article 53 of SIX Exchange Regulation Listing Rules Approval of delisting of ONE swiss bank SA’s registered sharesfrom SIX Swiss Exchange SIX Exchange Regulation AG (“SER”) approved the delisting of the registered shares of ONE swiss bank SA (“ONE”) from SIX Swiss Exchange. The last trading day will be Wednesday 6 March 2024. On 16 November 2023, ONE applied to SER for the delisting of its registered shares from SIX Swiss Exchange. Per decision dated 5 December 2023, SER approved the delisting of the ONE shares with a nominal value of    CHF 1.- each. The delisting date has been set for Thursday 7 March 2024. The last trading day on SIX Swiss Exchange will be 6 March 2024. For further information, please contact: Julien DelécrazInvestor Relations+41 58 300 78 13investorrelations@oneswiss.com ONE...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.